Physician profile
John M Simmons
NPI 1598733222
$2,693.08
in general payments reported to CMS, 2019-2025
19 companies · $339 in 2025
The $339 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $440 · 2020: $146 · 2021: $266 · 2022: $588 · 2023: $568 · 2024: $346 · 2025: $339.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,221 · Education: $17.84 · Entertainment: $14.13.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,221.17 |
| Education | $17.84 |
| Entertainment | $14.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $610.41 | 2019-2025 | Precision 1, Simbrinza, Precision7 |
| Sun Pharmaceutical Industries INC. | $512.70 | 2020-2025 | Cequa |
| Oyster Point Pharma, INC. | $242.21 | 2023 | Tyrvaya |
| Bausch & Lomb Americas INC. | $236.80 | 2022-2025 | Miebo, Xiidra |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $182.11 | 2019-2021 | |
| Allergan, INC. | $177.85 | 2020-2022 | |
| Abbvie INC. | $148.06 | 2022-2024 | |
| Coopervision INC. | $138.86 | 2019-2022 | |
| Glaukos Corporation | $135.37 | 2025 | Photrexa Viscous and Photrexa |
| Tarsus Pharmaceuticals, INC. | $95.22 | 2024-2025 | Xdemvy |
| Kala Pharmaceuticals, INC. | $37.12 | 2021 | |
| Quidel Corporation | $36.23 | 2023 | |
| Novartis Pharmaceuticals Corporation | $35.46 | 2019-2023 | |
| Eyevance Pharmaceuticals LLC | $26.88 | 2019-2021 | |
| Johnson & Johnson Vision Care, INC. | $19.77 | 2020 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dompe US, INC. | $17.12 | 2024 | Oxervate |
| Optos, INC. | $14.13 | 2024 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Harrow Eye, LLC | $13.60 | 2024 | Vevye |
| Biotissue Holdings INC. | $13.18 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Simmons listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.